Sanofi: As expected, Q2 2012 Business EPS(1) impacted by the loss of exclusivity of Plavix(R) and Avapro(R) in the U.S.

PARIS, July 26, 2012, 2012 /PRNewswire/ -- Sanofi

                           Q2 2012 Change on a      Change at     H1 2012 Change on a    Change at
                                     reported        constant                reported    constant
                                      basis  exchange rates(1)                  basis exchange rates
                                      -----   ----------------                  ----- --------------
    Net sales              EUR8,870m           +6.2%           +0.4% EUR17,381m       +7.8%          +3.6%
    Business net income(1) EUR1,944m           -9.6%           -17.6% EUR4,386m       +1.5%          -4.5%
    ---------------------  ---------           ----            -----  ---------       ----           ----
    Business EPS(1)         EUR1.48            -9.8%           -17.7%  EUR3.32        +0.6%          -5.2%
    --------------          -------            ----            -----   -------        ----           ----
    Commenting on the Group's performance in Q2 2012, Sanofi Chief Executive Officer, Christopher A. Viehbacher said,
    "This quarter, we faced the anticipated loss of exclusivity of Plavix(R) and Avapro(R) in the U.S.The strategy initiated at
    the end of 2008 focusing on the development of our growth platforms(2), coupled with continuous tight cost control and
    value-creating acquisitions allowed Sanofi to limit the impact on business EPS(1). In addition, we made progress in
    advancing our pipeline with the submission of Lemtrada(TM) (alemtuzumab)(3) to the U.S. and EU regulatory agencies as
    well as the recent initiation of a comprehensive Phase III program for an Anti-PCSK-9 monoclonal antibody4."
    ------------------------------------------------------------------------------------------------------------

www.sanofi.com (+) 33 1 53 77 46 46 - E-mail : (+) 33 1 53 77 45 45 - E-mail : MR@sanofi.com IR@sanofi.com

    Unless otherwise indicated,
     all sales growth figures in
     this press release are
     stated at constant exchange
     rates(1).
    ----------------------------

In the second quarter of 2012, Sanofi generated net sales of EUR8,870 million, up 6.2% on a reported basis. Exchange rate movements had a positive effect of 5.8 percentage points reflecting the appreciation of the U.S. dollar and, to a lesser extent, the appreciation of the Japanese Yen and Chinese Yuan against the Euro. At constant exchange rates, and adjusting for changes in the scope of consolidation (primarily the return of Copaxone to Teva and the disposal of Dermik), net sales increased by 2.5%.

Net sales in the first half of 2012 reached EUR17,381 million, an increase of 7.8% on a reported basis. Exchange rate movements had a favorable effect of 4.2 percentage points driven by the appreciation of the U.S. dollar, Japanese Yen and Chinese Yuan against the Euro. At constant exchange rates, and after taking into account changes in structure (primarily the consolidation of Genzyme from the second quarter of 2011), net sales increased by 1.0%.

In the second quarter of 2012, sales of the Group's growth platforms (including "new Genzyme") were EUR5,753 million, an increase of 7.6%, with double digit growth achieved by Diabetes and CHC, while Emerging Markets grew 9.8%. The Group's growth platforms accounted for 64.9% of total consolidated sales in the second quarter 2012, up from 60.9% in the second quarter of 2011. In the first half of 2012, growth platforms sales (including "new Genzyme") reached EUR11,134 million, an increase of 11.0% or 6.7% with Genzyme proforma (sales of Genzyme were not consolidated in the first quarter of 2011). Growth platforms sales comprised 64.1% of total consolidated sales compared with 60.1% for the first half of 2011.

Sales for the Pharmaceuticals business were EUR7,511 million in the second quarter of 2012, a decrease of 0.4%. The performance of growth platforms broadly offset the loss of sales of Copaxone (impact of EUR119 million), disposal of Dermik (impact of EUR29 million), EU austerity measures and generic competition (resulting in EUR163 million impact, mainly to Lovenox, Xatral and Taxoterein the U.S.; Taxotere, Plavix and Aprovel((R)) in the EU). First-half 2012 sales for the Pharmaceuticals business were EUR14,827 million, an increase of 4.0%, which reflects the positive contribution from Genzyme (consolidated from April 2011).

    (millions of euros)       Q2 2011 Change at constant H1 2012 Change at constant
                              net sales  exchange rates net sales    exchange rates
    ---                       ---------  -------------- ---------    --------------
    Lantus(R)                     1,228            +16.5%   2,346             +16.8%
    Apidra(R)                        56              0.0%     108              +2.0%
    Plavix(R)                       553             -1.0%   1,058              -0.6%
    Lovenox(R)                      489            -11.0%   1,015             -10.7%
    Eloxatin(R)                     375            +35.9%     759             +61.9%
    Aprovel(R)                      334             -5.8%     641              -5.9%
    Taxotere(R)                     159            -27.9%     309             -50.0%
    Multaq(R)                        64            -14.7%     127              -9.2%
    Jevtana(R)                       65            +27.1%     119             +18.8%
    Cerezyme(R)                     150            -13.9%     299            -4.6%*
    Myozyme(R) / Lumizyme(R)        113             +9.1%     225           +13.0%*
    Fabrazyme(R)                     74           +123.3%     121           +86.7%*
    Renvela(R)/Renagel(R)           165            +10.9%     312            +9.7%*
    Synvisc(R)/Synvisc One(R)       106             +9.0%     184            +8.9%*
    -------------------------       ---             ----      ---             -----

*On a constant structure basis and at constant exchange rates See Appendix 10 for definitions of financial indicators See Appendix 2 for a geographical split of consolidated net sales by product

The Diabetes business recorded another quarter of double-digit growth (up 13.7%) to EUR1,436 million driven by the strong performance of Lantus. Sales of increased 16.5% to EUR1,228 million supported by strong growth in the U.S. (sales +19.4% to EUR760 million), Emerging Markets (+20.6% to EUR198 million) and Japan (+25.9% to EUR40 million). In the U.S., Lantus SoloSTAR represented 51.9% of total Lantus sales in the quarter, versus 46.2% in the second quarter of 2011. In the Emerging Markets, Lantus sales growth were particularly strong in China (+34.9%), Mexico (+25.8%) and Russia (+14.0%). In May, Sanofi inaugurated a new assembling and packaging line to produce Lantus SoloSTAR at its Beijing plant in China. First-half sales of Lantus((R)) reached EUR2,346 million, up 16.8%.

The results from the ORIGIN trial were presented in June at the American Diabetes Association (ADA) Scientific Sessions and showed that Lantus had no statistically significant positive or negative impact on cardiovascular outcomes versus standard care during the study period. The results also showed that insulin glargine delayed progression from pre-diabetes to type 2 diabetes and there was no association between insulin glargine use and increased risk of any cancer.

Results of large-scale epidemiological studies, conducted by independent researchers in Northern Europe and in the United States were also presented at the ADA Scientific Sessions in June. These results provide further evidence that there was no increased risk of cancer in people with diabetes treated with Lantus, compared to those treated with other insulins.

Second-quarter sales of were stable at EUR56 million, reflecting the improvement in supply of Apidra 3mL cartridges. First-half net sales of Apidra reached EUR108 million, an increase of 2.0%.

Sales of decreased 5.5% to EUR110 million in the second quarter, reflecting generic competition in Japan (where sales decreased 28.6% to EUR34 million). In Emerging Markets, sales of Amaryl increased 14.0% to EUR68 million. First-half sales of Amaryl were EUR213 million, down 6.5%.

Sales from the business increased 7.0% to EUR751 million in the second quarter, largely attributable to another strong quarter for in the U.S. with sales of EUR313 million (up 53.3%). The U.S. market exclusivity of Eloxatin((R)) will expire on August 9, 2012. First-half sales of the oncology business were EUR1,492 million, an increase of 9.9%.

Second-quarter ((R)) sales stabilized (at EUR159 million) versus the previous quarter, but decreased 27.9%, versus the second quarter of 2011, reflecting generic erosion in the U.S. (EUR22 million, -44.1%) and Western Europe (EUR13 million, -74.5%). First-half sales of Taxotere were EUR309 million (down 50.0%), 77.7% of which (EUR240 million) was generated outside the U.S. and Western Europe.

Second-quarter sales of increased 27.1% to EUR65 million, supported by the commercial roll-out in Western Europe. First-half sales of the product reached EUR119 million, an increase of 18.8%.

((R))((R))

As expected, the Worldwide presence of ((R)) decreased 43.3% to EUR1,100 million in the second quarter, reflecting the loss of its exclusivity in the U.S. on May 17, 2012. During the period, sales in the U.S. (consolidated by Bristol-Myers Squibb) declined by 59.9% to EUR536 million. In Europe, where Plavix((R)) also faces generic competition, sales were down 18.5% to EUR121 million. Second-quarter consolidated sales in Emerging Markets increased 6.9% to EUR202 million, of which EUR96 million was generated in China (up 25.2%). In Japan, sales of Plavix((R)) recorded another quarter of double digit growth (up 19.0%) to EUR220 million. In the first half of 2012, the Worldwide presence of Plavix((R)) reached EUR2,862 million, a decrease of 23.1%.

(1 )See Appendix 10 for definitions of financial indicators

    (millions of euros) Q2 2012 Change at constant H1 2012 Change at constant
                                    exchange rates             exchange rates
    ---                             --------------             --------------
    Europe                  121              -18.5%    245              -18.6%
    United States           536              -59.9%  1,780              -30.4%
    Other Countries         443               -2.3%    837               -2.4%
    ---------------         ---               ----     ---               ----
    TOTAL                 1,100              -43.3%  2,862              -23.1%
    -----                 -----              -----   -----              -----

In the second quarter, the worldwide presence of decreased 22.3% to EUR382 million, due to generic competition. In the U.S., sales declined 69.6% reflecting the loss of exclusivity on March 30, 2012. Sanofi launched an authorized generic version in the U.S. Consolidated sales of the productin Emerging Markets reached EUR107 million, up 4.2%. In the first half of 2012, the worldwide presence of Aprovel reached EUR786 million, down 20.2%.

    (millions of euros) Q2 2012 Change at constant H1 2012 Change at constant
                                    exchange rates             exchange rates
    ---                             --------------             --------------
    Europe                  185              -13.5%    370              -12.2%
    United States            32              -69.6%    108              -51.4%
    Other Countries         165               -6.9%    308              -10.2%
    ---------------         ---               ----     ---              -----
    TOTAL                   382              -22.3%    786              -20.2%
    -----                   ---              -----     ---              -----

((R)) sales were EUR489 million in the second quarter, down 11.0%, reflecting generic pressure in the U.S. where sales declined 52.5% to EUR87 million. Sanofi commercializes an Authorized Generic of Lovenox((R)) in the U.S. (sales are booked in the Generics business). Outside the U.S., Lovenox((R)) recorded another quarter of growth with sales of EUR402 million (+6.6%). In Emerging Markets, sales increased 12.0% to EUR158 million. In Western Europe sales of the product reached EUR219 million, up 2.8%. First-half sales of Lovenox were EUR1,015 million (-10.7%), 79.4% of which (EUR806 million) was generated outside the U.S. (+ 9.2%).

Second-quarter sales of recorded double digit growth rate (up 10.9%) to EUR165 million, driven by a good performance in the U.S. (sales were up 23.8% to EUR111 million). First-half sales of Renvela((R))/Renagel((R)) were EUR312 million, up 9.7%*.

sales were EUR106 million, an increase of 9.0% in the second quarter, driven by the Synvisc One((R)) franchise in the U.S. (where sales of Synvisc((R))/Synvisc One increased 11.6% to EUR87 million). First-half sales of Synvisc((R))/Synvisc One((R)) reached EUR184 million, an increase of 8.9%*.

Second-quarter sales of the family of products were EUR129 million, (+1.7%), 60.5% of which (EUR78 million) was generated in Japan (+6.2%). First-half sales of the Ambien family were EUR254 million, up 1.7%. In Japan, first-half sales of Myslee reached EUR151 million, up 5.4%.

sales as a prescription drug were EUR126 million in the second quarter, down 2.5%, reflecting the impact in Japan of a mild allergy season compared to 2011 (sales of the product in Japan were down 12.5% to EUR88 million). First-half sales of Allegra were EUR308 million (down 14.0%), 78.2% of which (EUR241 million, down 19.7%) was generated in Japan. In July 2012, Sanofi entered into settlements in Japan with generic manufacturers regarding Allegra. Sanofi does not expect the entry of generics before March 2014.

(1 )See Appendix 10 for definitions of financial indicators On a constant structure basis and at constant exchange rates, Genzyme sales were not consolidated in Q1 2011

Sales of were EUR64 million, down 14.7%, reflecting the impact of updated labeling in the second half of 2011. Sales of the product in the U.S. were EUR50 million, down 4.3%. First-half sales of Multaq were EUR127 million, down 9.2%.

The transfer to Teva of sales was finalized in the first quarter of 2012. As a consequence, Sanofi did not book any sales of the product in the second quarter of 2012 compared to EUR119 million consolidated in the second quarter of 2011. Sanofi will receive a payment of 6% on sales from Teva for a period of two years, on a country-by-country basis. In the first half of 2012, Sanofi recorded EUR24 million of Copaxone sales compared to EUR233 million in the first half of 2011.

"New Genzyme" currently consists of Rare Diseases products and future Multiple Sclerosis products (Aubagio and Lemtrada(TM)).

    (EUR million) Q2 2012 Change at constant H1 2012    Change on a constant
                  net sales exchange rates net sales  structure basis and at
                                                     constant exchange rates
    ---           --------- -------------- --------- -----------------------
    Cerezyme(R)         150            -13.9%     299                 -4.6%*
    Myozyme(R) /
     Lumizyme(R)        113             +9.1%     225                +13.0%*
    Fabrazyme(R)         74           +123.3%     121                +86.7%*
    Other Rare
     Disease
     products            97            +13.9%     189                +11.2%*
    Total "new
     Genzyme"           434             +9.1%     834                +11.3%*
    ----------          ---             ----      ---                 ------

Second-quarter sales of were EUR434 million, an increase of 9.1%. First-half sales of "new Genzyme" reached EUR834 million, an increase of 11.3%*.

Sales of were EUR150 million in the second quarter, a decrease of 13.9%, reflecting the quarterly variability of order patterns and a strong comparable in the second quarter 2011. However, Genzyme remains on track to maintain market share and deliver modest Cerezyme growth throughout the year. First-half sales of Cerezyme((R)) reached EUR299 million (-4.6%*).

Second-quarter sales of reached EUR113 million, an increase of 9.1%. First-half sales of Myozyme((R))/Lumizyme reached EUR225 million, an increase of 13.0%*. In May, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved a second operation for filling and finishing product at the Genzyme manufacturing plant at Waterford, Ireland. With this approval, Genzyme has nearly doubled its ability to fill and finish Myozyme and Lumizyme produced at the 4,000 liter bioreactor scale. Genzyme will also begin the process to secure FDA and EMA approvals to fill and finish additional products in the second suite, with the long-term goal to use the Waterford site as a filling and finishing platform across its portfolio of products.

recovered significantly in the second quarter with sales up 123.3% to EUR74 million. First-half sales of Fabrazyme((R)) reached EUR121 million, an increase of 86.7%*. In March 2012, Genzyme began shipping Fabrazyme produced in its new plant in Framingham, MA, which was approved by the FDA and the EMA in January 2012. In March, treated patients in the U.S. returned to full dosing. In addition, new patients in the U.S. are eligible to begin Fabrazyme treatment, at full dosing levels. In Europe, the process of moving the most severely affected patients to full dose of Fabrazyme began in March 2012. Globally, the complete return to normal supply levels of Fabrazyme has begun and will continue throughout the year, as Genzyme works to obtain all global regulatory approvals for the Framingham plant and to build inventory.

During the quarter, Genzyme made significant progress towards building a leading franchise in multiple sclerosis (MS) with the filing of (TM) (alemtuzumab) in the U.S. and EU in June 2012 and the release of positive top-line results from the TOWER trial with (teriflunomide)(10). In addition, Genzyme initiated hiring the U.S. MS sales team.

On a constant structure basis and at constant exchange rates, Genzyme sales were not consolidated in Q1 2011 (10) Aubagio is the proprietary name submitted to health authorities

Second-quarter Consumer Health Care (CHC) sales were EUR738 million, an increase of 11.3%, reflecting the performance in Emerging Markets which included the contribution of Universal Medicare in India. In Emerging Markets, sales of Essentiale((R)), Lactacyd((R)), Enterogermina((R)), Maalox((R)), NoSpa((R) )and Haowawa((R)) recorded double digit growth. CHC sales in Latin America, Asia and Russia grew by 18.1%, 41.3% and 26.7%, respectively. In Western Europe, Doliprane((R)), Maalox((R)) and MagneB6((R)) showed good performance resulting from greater promotional focus. In the U.S., sales were EUR157 million, down 3.4%, due to lower sales of Allegra((R)) OTC (down 23.7% to EUR54 million) reflecting inventory build at the retail level in the second quarter of 2011 to ensure proper supply during launch. First-half sales of Consumer Health Care reached EUR1,543 million, an increase of 11.4%.

Second-quarter sales of generics reached EUR468 million, up 7.8%, led by the U.S. performance which benefited from the launch of the authorized generics of Lovenox((R)) and Aprovel((R)) (U.S. sales of generic products increased 76.5% to EUR67 million). In Emerging Markets, sales of generics were EUR277 million, up 2.5%, despite lower sales in Eastern Europe. First-half sales of generics were EUR907 million, an increase of 7.2%.

Second-quarter consolidated sales of Sanofi Pasteur were EUR783 million, an increase of 3.0%, supported by another record performance for seasonal influenza vaccines in Southern Hemisphere and despite temporarily order limitations for Pentacel((R)) in the U.S. First-half consolidated net sales for the Human Vaccines business were EUR1,400 million, an increase of 1.5%.

Sales of increased 40.4% to EUR80 million in the second quarter of 2012, reflecting the positive impact of a later timing of supply than last year in the Southern Hemisphere and strong demand. 2012 was another record performance for seasonal influenza vaccines in the Southern Hemisphere for Sanofi Pasteur. First-half sales of seasonal influenza vaccines reached EUR167 million compared to EUR158 million in the first half of 2011. In July 16, 2012, Sanofi Pasteur, announced that the first lots of Fluzone vaccine began shipping to U.S. health care providers. This initial shipment represents the first of more than 60 million doses of seasonal influenza vaccine the company plans to deliver in the U.S. this influenza season

Second-quarter sales of reached EUR273 million, down 5.2% reflecting some order limitations for the 5-in-1 combination vaccines Pentacel in the U.S. (sales were EUR62 million, down 28.6%)Sanofi Pasteur has effectively temporarily implemented order limitations for Pentacel and Daptacel vaccines from April 2012 in the U.S. These ordering limitations are likely to remain in effect until the beginning of 2013. This is a necessary step due to a manufacturing delay that will temporarily reduce supply below the level needed to fully satisfy market demand in the U.S. Despite strong growth in China in the second quarter, Pentaxim sales were impacted by phasing deliveries in Mexico and reached EUR60 million, down 10.8%. Emerging Markets sales of Polio/Pertussis/Hib vaccines increased 14.4% to EUR131 million in the second quarter. First-half sales ofPolio/Pertussis/Hib vaccines reached EUR518 million, down 0.4%.

In April, the Japanese Ministry of Health, Labor and Welfare approved the Sanofi Pasteur's standalone Inactivated Poliovirus Vaccine (Imovax Polio) against acute flaccid poliomyelitis. Imovax Polio will be added to the country's public immunization program on September 1(st), 2012.

Furthermore, in June, Hexaxim(TM) (DTaP-IPV-Hib-HepB vaccine) received a positive scientific opinion from the European Medicines Agency (EMA), as part of a procedure designed to evaluate medicinal products intended for markets outside the European Union. This is the first time the EMA gave a positive scientific opinion to a vaccine following that procedure.

Second-quarter sales of were EUR111 million, up 2.2% despite competition in the U.S. First-half sales for Menactra were EUR167 million, an increase of 10.5%.

vaccines sales recorded a 20.9% increase in the second quarter to EUR146 million, reflecting the strong performance of Adacel((R)) in the U.S. (total sales of Adacel((R)) were up 30.7% to EUR100 million). First-half consolidated net sales for Adult boosters were EUR233 million, an increase of 5.3%.

Second-quarter and first-half sales of were EUR100 million (up 5.6%) and EUR177 million (stable), respectively.

On July 12, Sanofi Pasteur received a Warning Letter following regular inspections conducted this year at manufacturing facilities in Toronto, Canada and Marcy L'Etoile, France this year. Sanofi Pasteur takes seriously the observations regarding the US licensed products and their related production units. We are working diligently with the FDA to implement a series of immediate and ongoing steps to address the issues identified in the Warning Letter and further strengthen our manufacturing operations and quality systems.

     (millions of euros)                                             Q2 2012 Change at constant H1 2012 Change at constant
                                                                     net sales  exchange rates net sales    exchange rates
    ---                                                              ---------  -------------- ---------    --------------
    Influenza Vaccines (incl. Vaxigrip(R) and Fluzone(R))                   80            +40.4%     169              +5.7%
              of  which seasonal vaccines                                   80            +40.4%     167              +4.4%
              of  which pandemic vaccines                                    0                -        2                Ns
    Polio/Pertussis/Hib Vaccines (incl. Pentacel(R) and Pentaxim(R))       273             -5.2%     518              -0.4%
    Meningitis/Pneumonia Vaccines (incl. Menactra(R))                      129             -3.3%     202              +2.7%
    Adult Booster Vaccines (incl. Adacel (R))                              146            +20.9%     233              +5.3%
    Travel and Other Endemics Vaccines                                     100             +5.6%     177               0.0%
    Other Vaccines                                                          55            -19.7%     101              -3.1%
    --------------                                                         ---            -----      ---              ----
    TOTAL                                                                  783             +3.0%   1,400              +1.5%
    -----                                                                  ---             ----    -----              ----

Second-quarter sales of(not consolidated)the joint venture with Merck & Co. in Europe, increased 3.8% to EUR176 million, driven by travel and other endemic vaccines. Sales of Gardasil((R)) stabilized (down 2.2%) at EUR46 million. First-half sales of grew 7.7% to EUR332 million.

Sales of increased 9.1% to EUR576 million in the second quarter of 2012, driven by the U.S. (up 17.8% to EUR261 million) and Emerging Markets (up 10.9% to EUR143 million). First-half sales of Merial reached EUR1,154 million, an increase of 1.2%.

Second-quarter sales of the segment were up 10.2% to EUR385 million, reflecting strong performance of the Frontline((R))/Fipronil family of products with sales up 11.1% to EUR228 million driven by the U.S. (sales of Frontline((R)) family products increased by 18.8% to EUR135 million). First-half sales of the companion animals segment reached EUR784 million, up 1.0%.

On June 6, 2012, Merial filed a patent infringement complaint against Velcera for its new PetArmor Plus product and requested an hearing for a preliminary injunction. On June 29(th), the Court granted the motion enjoining Velcera from selling their new product. Velcera has appealed that decision to the Federal Circuit. The patent infringement trial is scheduled for November 2012.

The segment reported sales of EUR191 million in the second quarter, up 6.9%, driven by the Avian segment (up 10.8%) and the Swine segment (+33.3%) which includes the acquisition of Newport Laboratories in the U.S. and completed in March. First-half sales of the production animals segment were EUR370 million, up 1.7%.

    (millions of euros)                  Q2 2012 Change at constant H1 2012 Change at constant
                                         net sales  exchange rates net sales    exchange rates
    ---                                  ---------  -------------- ---------    --------------
    United States                            2,795             +3.0%   5,395              +8.8%
    Western Europe*                          2,136            -11.0%   4,361              -6.4%
    Emerging Markets**                       2,823             +9.8%   5,447              +9.9%
      of which Eastern Europe and Turkey       670             -0.1%   1,327              +1.0%
      of which Asia                            716            +12.7%   1,381             +12.2%
      of which Latin America                   887            +12.7%   1,675             +14.2%
      of which Africa                          255             +8.4%     507              +9.4%
      of which Middle East                     267            +25.9%     494             +15.6%
      --------------------                     ---            -----      ---             -----
    Rest of the world***                     1,116             -2.5%   2,178              -0.7%
    -------------------                      -----             ----    -----              ----
      of which Japan                           796             -0.1%   1,529              +0.9%
      --------------                           ---             ----    -----              ----
    TOTAL                                    8,870             +0.4%  17,381              +3.6%
    -----                                    -----             ----   ------              ----

* France, Germany, UK, Italy, Spain, Greece, Cyprus, Malta, Belgium, Luxembourg, Portugal, Netherlands, Austria, Switzerland, Sweden, Ireland, Finland, Norway, Iceland, Denmark ** World less the U.S. and Canada, Western Europe, Japan, Australia and New Zealand *** Japan, Canada, Australia and New Zealand

Second-quarter sales in increased 9.8% to EUR2,823 million. This performance was supported by the broad geographic footprint of the Group and its diversified portfolio of products in Emerging Markets (Rx drugs, branded generics, CHC, new Genzyme, Vaccines and Animal Health). In the second quarter, in Emerging Markets Diabetes, Vaccines and CHC recorded strong double digit growth, up 19.1%, up 22.9% and up 26.9%, respectively. BRIC (Brazil, Russia, India and China) sales were EUR995 million, an increase of 15.2%. Sales in China reached EUR320 million, up 20.9%, reflecting the growth of Plavix, Lantus and Vaccines. Brazil sales grew 14.0% to EUR405 million, up driven by Vaccines and CHC. Sales in Russia were EUR203 million, an increase of 9.0%, led by the performance of Lantus, CHC and generics. Emerging Marketsreported first-half sales of EUR5,447 million, up 9.9% (or 7.7% with Genzyme proforma).

In the , sales reached EUR2,795 million in the second quarter, an increase of 3.0%. The sales growth of Lantus, Eloxatin and contribution from authorized generics and Animal Health offset the impact of generic competition for Lovenox, Taxotere and the disposal of Dermik. First-half sales in the U.S. increased 8.8% to EUR5,395 million (or up 1.0% with Genzyme pro forma).

Second-quarter sales in decreased 11.0% to EUR2,136 million. Sales were impacted by the transfer of the Copaxone business to Teva, generic competition for Taxotere, Aprovel and Plavix, as well as the impact of austerity measures. Excluding the impact of Copaxone, sales in Western Europe declined 6.6%. First-half sales in Western Europewere EUR4,361 million, a decline of 6.4%, (or down 6.5% with Genzyme pro forma and excluding Copaxone).

Sales in were stable at EUR796 million in the second quarter. Despite good performance from Plavix and Lantus, sales in Japan were impacted by biannual price cuts, generic competition to Amaryl, lower sales in Vaccines and Allegra due to a mild allergy season. First-half sales in Japan increased 0.9% to EUR1,529 million (or down 2.6% with Genzyme pro forma).

Since the last R&D update on April 27, 2012, there has been important newsflow for Sanofi R&D. Several dossiers were submitted to regulatory authorities; positive clinical trials results were announced; a large Phase III program for the anti-PCSK9 monoclonal antibody (SAR236553, collaboration with Regeneron) was initiated as planned; several compounds entered Phase I and a collaboration with the Joslin Diabetes Center was signed.

At the end of July, the R&D portfolio comprises 64 NMEs (New Molecular Entities) projects and vaccines in clinical development of which 18 are in Phase III or have been submitted to the health authorities for approval.

Several regulatory milestones were achieved during the period:

In May, additional positive results from a Phase II trial of , a subcutaneously administered, fully-human monoclonal antibody targeting PCSK9, in patients with heterozygous familial hypercholesterolemia (heFH) were presented at the European Atherosclerosis Society Congress. The trial randomized 77 patients with heFH whose LDL-cholesterol (LDL-C) levels remained uncontrolled on statin therapy with or without ezetimibe. Across the four different dosing regimens tested, patients receiving SAR236553 for 12 weeks achieved a mean LDL-C reduction from baseline of 28.9% to 67.9%, compared to 10.7% in patients receiving placebo (p<0.05). The results from this study were also published online in . Positive data from two Phase II trials in primary hypercholesterolemia were also presented at the American College of Cardiology's Annual Scientific Meeting in March.

Several trials of ODYSSEY, the Phase III clinical program of SAR236553, have now initiated patient enrollment. This program will enroll more than 22,000 patients and consists of over ten clinical trials evaluating the effect of SAR236553 on the lowering of LDL cholesterol and an 18,000 patient cardiovascular outcomes study. Internally, Sanofi has also created a dedicated PCSK9 Development & Launch Unit which underscores Sanofi's commitment to develop this potential first-in-class therapeutic agent.

In June, the results of2Phase III trials, GetGoal Duo 1 and GetGoal-L, evaluating (lixisenatide), a once-daily investigational GLP-1 agonist, in combination with basal insulin plus oral anti-diabetic agents, were presented at ADA Scientific Sessions in June. These two studies achieved the primary efficacy endpoint of HbA1c improvement with an associated significant reduction in post-prandial glucose in people with type 2 diabetes who were either new to insulin therapy (as early as 12 weeks after initiation) or already treated with insulin (for an average of 3.1 years).

In addition, the results of the trial were presented in June at the American Diabetes Association (ADA) Scientific Sessions Scientific Sessions and showed that had no statistically significant positive or negative impact on cardiovascular (CV) outcomes versus standard care during the study period. The results also showed that insulin glargine delayed progression from pre-diabetes to type 2 diabetes and there was no association between insulin glargine use and increased risk of any cancer. Results of a large-scale epidemiological program in Europe and the U.S. were also presented at the ADA Scientific Sessions in June. These results provide further evidence that there was no increased risk of cancer in people with diabetes treated with Lantus, compared to those treated with other insulins. Lantus is the most studied basal insulin with over 10 years of scientific data and real life experience.

In June, Genzyme announced top-line results from the TOWER trial that assessed the efficacy and safety of once-daily, oral (teriflunomide) in patients with relapsing forms of multiple sclerosis (MS). In the study, patients receiving teriflunomide 14 mg had a statistically significant reduction of 36.3% in annualized relapse rate and 31.5% reduction in the risk of 12-week sustained accumulation of disability. Analysis of the full TOWER data is ongoing and results will be presented at a forthcoming scientific meeting. These results are consistent with the results observed in the Phase III TEMSO study. Marketing applications for teriflunomide for the treatment of relapsing forms of MS are under review by the FDA, the EMA and other regulatory authorities.

In July, Sanofi Pasteur announced that its tetravalent candidate demonstrated proof of efficacy against dengue, a threat to almost 3 billion people, in the world's first ever dengue efficacy trial. The results of this study conducted in Thailand confirm the excellent safety profile of the vaccine. The vaccine generated antibody response for all four dengue virus serotypes. Evidence of protection was demonstrated against three of the four virus serotypes circulating in Thailand. Analyses are ongoing to understand the lack of protection for the fourth serotype in the particular epidemiological context of Thailand. The full data resulting from this first efficacy trial are currently under review by scientific and clinical experts, as well as public health officials. Detailed results of this study will be published in a peer-reviewed journal and presented to the scientific community later this year.Large scale phase III dengue vaccine clinical studies with 31,000 participants are underway in 10 countries of Asia and Latin America. These studies will generate important additional data in a broader population and in a variety of epidemiological settings to demonstrate vaccine efficacy against the four circulating dengue virus serotypes.

On June 20, 2012 was reviewed by the U.S. FDA's Oncologic Drugs Advisory Committee. The committee voted to recommend against approval of semuloparin for the prophylaxis of venous thromboembolism (VTE) in patients receiving chemotherapy for certain type of cancer. In July, Sanofi decided to withdraw all applications for marketing authorization for semuloparin following comments by regulatory agencies.

It has been decided not to pursue registration of (Clolar) in acute myeloid leukemia (AML). A Phase II study, evaluating , a vascular disrupting agent, in non-small cell lung cancer (NSCLC) did not meet its primary endpoint. The recruitment of patients of the Phase III study, evaluating ombrabulin in sarcoma, is now completed. The results of the randomized, open-label, phase II study conducted in Europe evaluating in association with paclitaxel versus paclitaxel single-agent as neoadjuvant therapy in patients with stage II-IIIA triple negative breast cancer did not show any advantage in efficacy.

Four compounds entered Phase I:

A new collaboration to promote the development of new medicines for the treatment of diabetes and related disorders was also signed in June between Sanofi and the Joslin Diabetes Center, a teaching and research affiliate of Harvard Medical School.

Sanofi decided to discontinue the BiTE((R)) antibody project and to terminate its collaboration with Micromet.

Sanofi generated second-quarter of EUR8,870 million, up 6.2% on a reported basis (+0.4% at constant exchange rates), reflecting the performance of growth platforms, the impact from EU austerity measures, the loss of EUR163 million of sales due to generic competition and a favorable currency effect. First-half sales were EUR17,381 million, an increase of 7.8% on a reported basis (+3.6% at constant exchange rates), also reflecting the consolidation of Genzyme from April 2011 and the loss of EUR398 million of sales due to generic competition.

were down 41.5% (or down 45.7% at constant exchange rates) to EUR247 million in the second quarter due to the loss of exclusivity of Plavix and Avapro in the U.S. on May 17 and March 30, respectively. First-half other revenues were down 19.4% to EUR673 million (or down 23.4% at constant exchange rates).

reached EUR6,387 million in the second quarter, an increase of 3.3% (or a decrease of 3.5% at constant exchange rates). The ratio of cost of sales to net sales was virtually flat at 30.8%, 0.2 percentage points lower versus the second quarter of 2011, reflecting a favorable currency effect and industrial productivity enhancement which offset the negative evolution of the product mix. First-half gross profit reached EUR12,711 million, up 5.8% (or up 0.8% at constant exchange rates). In the first half of 2012, the ratio of cost of sales to net sales was 30.8%, 0.1 percentage points higher.

were EUR1,239 million in the second quarter, an increase of 3.5%. At constant exchange rates, R&D expenses decreased 1.2% due to tight cost control on internal costs, ongoing transformation initiatives, which more than offset significant investment in late-stage portfolio. The ratio of R&D expenses to net sales was 14.0%, down 0.3 percentage points versus the second quarter of 2011. First-half R&D expenses reached EUR2,415 million, up 5.1% (or down 3.6% with Genzyme proforma and at constant exchange rates). In the first half of 2012, the ratio of R&D expenses to net sales was 13.9%, versus 14.2% in the first half of 2011.

were EUR2,289 million in the second quarter, an increase of 0.9%. At constant exchange rates, SG&A decreased 4.3% due to a tight control especially in mature areas coupled with synergies derived from the Genzyme integration despite continued investment in growth platforms. The ratio of selling and general expenses to net sales was 25.8%, down 1.4 percentage points versus the second quarter of 2011. First-half SG&A expenses reached EUR4,410 million, up 5.0% (or -4.6% with Genzyme proforma and at constant exchange rates). In the first half of 2012, the ratio of selling and general expenses to net sales was 25.4%, versus 26.0% in the first half of 2011.

was a charge of EUR152 million in the second quarter of 2012 versus income of EUR7 million in the second quarter of 2011. In 2012, this line included an additional pre-tax reserve of EUR118 million linked to ramipril litigation in Canada. This line also includes a slight foreign exchange loss compared to a slight gain in the second quarter of 2012. In the first half of 2012, other current operating income net of expenses, which benefited from a settlement of a license litigation booked in the first quarter, was a loss of EUR5 million compared to an income of EUR23 million in the first half of 2011.

In the second quarter, the was EUR122 million, down 56.1% (or down 60.1% at constant exchange rates) due to the loss of exclusivity of Plavix and Avapro in the U.S. The share of after-tax profits from the territories managed by BMS under the Plavix((R)) and Avapro((R)) alliance dropped 55.5% to EUR122 million. First-half share of profits from associatesreached EUR419 million, down 26.5% (or down 30.4% at constant exchange rates), EUR417 million of which was attributed to BMS alliance.

wereEUR50 million in the second quarter, a decrease of 13.8%, reflecting lower profits paid to BMS from territories managed by Sanofi (EUR44 million versus EUR53 million in Q2 2011) as a result of generic competition in Europe. In the first half of 2012, non-controlling interestswereEUR104 million, down 23.5%.

Second-quarterwas EUR2,779 million, down 5.6% (or down 13.6% at constant exchange rates). The ratio of business operating income to net sales reached 31.3%, compared to 35.3% in the second quarter of 2011. First-half business operating income increased3.8%(or decreased 2.2% at constant exchange rates) toEUR6,196 million. The ratio of business operating income to net sales was 35.6%, down 1.4 percentage points compared to the first half of 2011.

(1) See Appendix 10 for definitions of financial indicators, and Appendix 6 for reconciliation of business net income to consolidated net income attributable to equity holders of Sanofi

reached EUR108 million, compared to EUR100 million in the second quarter of 2011.First-half-net financial expenses were EUR227 million versus EUR178 million in the first half of 2011 which included the financing of the Genzyme acquisition only for a quarter.

The effective was28.0compared to 26.5% in the second quarter of 2011. The first-halfeffective 28.0% compared to 27.5% in the first half of 2011.

reached EUR1,944 million in the second quarter, down 9.6% (or down 17.6% at constant exchange rates). First-half business net income was EUR4,386 million, up 1.5% (or down 4.5% at constant exchange rates).

    In the second quarter of 2012,
     Business earnings per
     share(1)(EPS) was EUR1.48, down
     9.8% and down 17.7% on a
     reported basis and at constant
     exchange rates, respectively.
     The average number of shares
     outstanding increased to 1,317.4
     million this quarter versus
     1,311.6 million in the second
     quarter of 2011.

    In the first half of 2012,
     Business earnings per
     share(1)(EPS) was EUR3.32 up
     0.6% and down 5.2% on a reported
     basis and at constant exchange
     rates, respectively. The average
     number of shares outstanding
     increased to 1,319.3 million in
     the first half of 2012 versus
     1,308.6 million in the first
     half of 2011.
    ---------------------------------

In the first half of 2012, the main reconciling items between business net income and consolidated net income attributable to equity holders of Sanofi were:

(1) See Appendix 10 for definitions of financial indicators, and Appendix 6 for reconciliation of business net income to consolidated net income attributable to equity holders of Sanofi

Net cash generated by operating activities after changes in working capital and before restructuring costs was EUR4,649 million in the first half of 2012, an increase of 6.6% compared to the first half of 2011. This amount covered a large part of capital expenditures (EUR711 million), dividend paid by Sanofi (EUR3,487 million), repurchasing of shares (EUR454 million), acquisitions and partnerships (EUR254 million) and restructuring costs (EUR504 million). As a consequence, net debt increased from EUR10,859 million at December 31, 2011 to EUR11,347 million at June 30, 2012 (debt of EUR15,654 million, net of EUR4,307 million cash and cash equivalents).

***********************

Limited review procedures on the half-year consolidated financial statements are complete. The limited review opinion is currently issuing.

***********************

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

    Appendix 1: 2012 second-quarter and
     2012 first-half consolidated net
     sales by product
    Appendix 2: 2012 second-quarter and
     2012 first-half consolidated net
     sales by geographic region and
     product
    Appendix 3: Consolidated net sales by
     business segment
    Appendix 4: Net sales of Growth
     Platforms
    Appendix 5: 2012 second-quarter and
     2012 first-half business net income
     statement
    Appendix 6: Reconciliation of
     business net income to net income
     attributable to equity holders of
     Sanofi
    Appendix 7: 2012 second-quarter and
     2012 first-half consolidated income
     statement
    Appendix 8: Change in net debt
    Appendix 9: Simplified consolidated
     balance sheet
    Appendix 10: Definitions of non-GAAP
     financial indicators
    (EUR million)                               Q2 2012 Change at constant Change on a reported
                                                net sales      exchange rates     basis
    ---                                         ---------      --------------     -----
    Lantus(R)                                             1,228                 16.5%             26.7%
    Apidra(R)                                                56                  0.0%              5.7%
    Amaryl(R)                                               110                 -5.5%              0.9%
    Insuman(R)                                               33                  3.0%              0.0%
       Total Diabetes                                     1,436                 13.7%             22.9%
    Taxotere(R)                                             159                -27.9%            -22.1%
    Eloxatin(R)                                             375                 35.9%             51.2%
    Jevtana(R)                                               65                 27.1%             35.4%
    Other Oncology                                          152                  0.0%              7.0%
       Total Oncology                                       751                  7.0%             17.0%
    Lovenox(R)                                              489                -11.0%             -8.8%
    Plavix(R)                                               553                 -1.0%              8.4%
    Aprovel(R)                                              334                 -5.8%             -2.6%
    Allegra(R)                                              126                 -2.5%              5.9%
    Stilnox(R)/Ambien(R)/Ambien CR(R)/Myslee(R)             129                  1.7%             11.2%
    Copaxone(R)                                               0               -100.0%           -100.0%
    Depakine(R)                                             102                  0.0%              2.0%
    Tritace(R)                                               93                 -2.1%             -2.1%
    Multaq(R)                                                64                -14.7%             -5.9%
    Xatral(R)                                                36                -46.9%            -43.8%
    Actonel(R)                                               36                -18.6%            -16.3%
    Nasacort(R)                                              19                -38.7%            -38.7%
    Renagel(R)/ Renvela(R)                                  165                 10.9%             20.4%
    Synvisc(R)/ Synvisc one(R)                              106                  9.0%             19.1%
    --------------------------                              ---                  ---              ----
    Cerezyme(R)                                             150                -13.9%             -9.6%
    Myozyme(R)                                              113                  9.1%             14.1%
    Fabrazyme(R)                                             74                123.3%            146.7%
    Other Rare Diseases products                             97                 13.9%             22.8%
       New Genzyme                                          434                  9.1%             16.0%
    Other Rx Drugs                                        1,432                 -8.8%             -5.5%
    Consumer Health Care                                    738                 11.3%             14.6%
    Generics                                                468                  7.8%              7.8%
    --------                                                ---                  ---               ---
    Total Pharmaceuticals                                 7,511                 -0.4%              5.1%
    ---------------------                                 -----                 ----               ---
    Vaccines                                                783                  3.0%             10.9%
    --------                                                ---                  ---              ----
    Animal Health                                           576                  9.1%             16.1%
    -------------                                           ---                  ---              ----
    Total                                                 8,870                  0.4%              6.2%
    -----                                                 -----                  ---               ---
    (EUR million)                      Q2 2012 Change at constant Change on a reported
                                       net sales    exchange rates       basis
    ---                                ---------    --------------       -----
    Polio/Pertussis/Hib Vaccines                 273                -5.2%               2.2%
    Influenza Vaccines                            80                40.4%              40.4%
    Meningitis/Pneumonia Vaccines                129                -3.3%               6.6%
    Adult Booster Vaccines                       146                20.9%              32.7%
    Travel and Other Endemics Vaccines           100                 5.6%              11.1%
    Other Vaccines                                55               -19.7%              -9.8%
    --------------                               ---               -----               ----
    Total Vaccines                               783                 3.0%              10.9%
    --------------                               ---                 ---               ----

Animal Health

    (EUR million)     Q2 2012 Change at constant Change on a reported
                     net sales     exchange rates       basis
    ---              ---------     --------------       -----
    Frontline(R) and
     other fipronil
     products                  228                11.1%               20.6%
    Vaccines                   180                 8.8%               13.2%
    Avermectin                 107                 6.5%               15.1%
    Others                      61                 7.3%               10.9%
    ------                     ---                 ---                ----
    Total                      576                 9.1%               16.1%
    -----                      ---                 ---                ----
    (EUR million)                               H1 2012 Change at constant Change on a reported
                                                net sales        exchange rates   basis
    ---                                         ---------        --------------   -----
    Lantus(R)                                              2,346                 16.8%           23.9%
    Apidra(R)                                                108                  2.0%            5.9%
    Amaryl(R)                                                213                 -6.5%           -1.8%
    Insuman(R)                                                65                  3.1%            1.6%
       Total Diabetes                                      2,747                 14.0%           20.4%
    Taxotere(R)                                              309                -50.0%          -47.3%
    Eloxatin(R)                                              759                 61.9%           74.1%
    Jevtana(R)                                               119                 18.8%           24.0%
    Other Oncology                                           305                    -               -
       Total Oncology                                      1,492                  9.9%           16.8%
    Lovenox(R)                                             1,015                -10.7%           -9.3%
    Plavix(R)                                              1,058                 -0.6%            6.4%
    Aprovel(R)                                               641                 -5.9%           -3.3%
    Allegra(R)                                               308                -14.0%           -8.1%
    Stilnox(R)/Ambien(R)/Ambien CR(R)/Myslee(R)              254                  1.7%            9.5%
    Copaxone(R)                                               24                -90.1%          -89.7%
    Depakine(R)                                              202                  1.5%            3.1%
    Tritace(R)                                               180                 -6.7%           -7.2%
    Multaq(R)                                                127                 -9.2%           -3.1%
    Xatral(R)                                                 69                -48.1%          -46.5%
    Actonel(R)                                                72                -23.1%          -20.9%
    Nasacort(R)                                               38                -50.0%          -48.6%
    Renagel(R)/ Renvela(R)                                   312                    -               -
    Synvisc(R)/ Synvisc1(R)                                  184                    -               -
    -----------------------                                  ---                  ---             ---
    Cerezyme(R)                                              299                    -               -
    Myozyme(R)                                               225                    -               -
    Fabrazyme(R)                                             121                    -               -
    Other Rare Diseases products                             189                    -               -
       New Genzyme                                           834                    -               -
    Other Rx Drugs                                         2,820                 -5.3%           -7.4%
    Consumer Health Care                                   1,543                 11.4%           13.8%
    Generics                                                 907                  7.2%            7.0%
    --------                                                 ---                  ---             ---
    Total Pharmaceuticals                                 14,827                  4.0%            8.0%
    ---------------------                                 ------                  ---             ---
    Vaccines                                               1,400                  1.5%            7.0%
    --------                                               -----                  ---             ---
    Animal Health                                          1,154                  1.2%            5.9%
    -------------                                          -----                  ---             ---
    Total                                                 17,381                  3.6%            7.8%
    -----                                                 ------                  ---             ---

Vaccines

    (EUR million)                      H1 2012 Change at constant Change on a reported
                                       net sales       exchange rates    basis
    ---                                ---------       --------------    -----
    Polio/Pertussis/Hib Vaccines                   518                -0.4%             4.9%
    Influenza Vaccines                             169                 5.7%             7.0%
    Meningitis/Pneumonia Vaccines                  202                 2.7%            10.4%
    Adult Booster Vaccines                         233                 5.3%            13.1%
    Travel and Other Endemics Vaccines             177                 0.0%             3.5%
    Other Vaccines                                 101                -3.1%             5.2%
    --------------                                 ---                ----              ---
    Total Vaccines                               1,400                 1.5%             7.0%
    --------------                               -----                 ---              ---

Animal Health

    (EUR million)     H1 2012   Change at constant Change on a reported
                     net sales       exchange rates       basis
    ---              ---------       --------------       -----
    Frontline(R) and
     other fipronil
     products                    468                -3.5%                2.0%
    Vaccines                     345                 3.4%                6.2%
    Avermectin                   221                 5.1%               11.6%
    Others                       120                 7.4%               11.1%
    ------                       ---                 ---                ----
    Total                      1,154                 1.2%                5.9%
    -----                      -----                 ---                 ---

Pharmaceuticals

                                   Q2 net sales (EUR million) Western Change at         United Change at      Emerging Change at Rest of the Change at
                                                              Europe        CER         States       CER        Markets       CER        World  CER
    ---                                                       ------        ---         ------       ---        -------       ---        -----  ---
    Lantus(R)                                                           194       1.6%           760      19.4%           198      20.6%          76     25.5%
    Apidra(R)                                                            18     -10.0%            18     -16.7%            13      18.2%           7     75.0%
    Amaryl(R)                                                             8     -11.1%             1       0.0%            68      14.0%          33    -31.0%
    Insuman(R)                                                           24      -7.7%             0         -              9      28.6%           0        -
    ---------                                                           ---       ----           ---       ---            ---      ----          ---      ---
       Total Diabetes                                                   251       0.4%           781      18.5%           288      19.1%         116      5.9%
    Taxotere(R)                                                          13    

Posted: July 2012


View comments

Hide
(web3)